Jun 15, 2023, 15:56
Patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes – Elie G. Dib
Excited to share that our study, published in JCO Precision Oncology, sheds light on the antitumor activity of pertuzumab plus trastuzumab (P + T) in advanced lung cancer patients with ERBB2 mutation or amplification. The Targeted Agent and Profiling Utilization Registry (TAPUR) Study demonstrated promising results, with a disease control rate of 37% and an objective response rate of 11%. Notably, patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes. These findings offer hope for heavily pretreated non-small-cell lung cancer patients. Grateful to the team and the American Society of Clinical Oncology for their support.